

The Endocrine Society's  
CLINICAL | GUIDELINES

Case Detection, Diagnosis,  
and Treatment of Patients  
with Primary Aldosteronism:  
An Endocrine Society Clinical Practice Guideline



THE JOURNAL OF  
CLINICAL  
ENDOCRINOLOGY  
& METABOLISM

**Authors:** John W. Funder, Robert M. Carey, Carlos Fardella, Celso E. Gomez-Sanchez, Franco Mantero, Michael Stowasser, William F. Young Jr., and Victor M. Montori

**Affiliations:** Prince Henry's Institute of Medical Research (J.W.F.), Clayton; Australia; University of Virginia Health System (R.M.C.), Charlottesville, Virginia; Facultad de Medicina Pontificia Universidad Católica de Chile (C.E.), Santiago; Chile; G.V. (Sonny) Montgomery VA Medical Center (C.E.G-S.), Jackson, Mississippi; University of Padova (F.M.), Padua; Italy; University of Queensland (M.S.), Brisbane; Australia; and Mayo Clinic (W.F.Y., V.M.M.), Rochester, Minnesota.

**Co-Sponsoring Associations:** European Society of Endocrinology, European Society of Hypertension, International Society of Endocrinology, International Society of Hypertension, The Japanese Society of Hypertension

**Disclaimer Statement:** Clinical Practice Guidelines are developed to be of assistance to endocrinologists by providing guidance and recommendations for particular areas of practice. The Guidelines should not be considered inclusive of all proper approaches or methods, or exclusive of others. The Guidelines cannot guarantee any specific outcome, nor do they establish a standard of care. The Guidelines are not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the independent judgment of health care providers and each patient's individual circumstances.

The Endocrine Society makes no warranty, express or implied, regarding the Guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. The Society shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.

First published in the *Journal of Clinical Endocrinology & Metabolism*, September 2008, 93(9): 3266–3281

© The Endocrine Society, 2008



THE JOURNAL OF  
CLINICAL  
ENDOCRINOLOGY  
& METABOLISM

The Endocrine Society's  
CLINICAL | GUIDELINES

Case Detection, Diagnosis,  
and Treatment of Patients  
with Primary Aldosteronism:  
An Endocrine Society Clinical Practice Guideline



THE JOURNAL OF  
CLINICAL  
ENDOCRINOLOGY  
& METABOLISM

# Table of Contents

Summary of Recommendations .....	4
Methods of Development of Evidence-Based Recommendations .....	5
Definition and Clinical Significance of Primary Aldosteronism .....	5
Case Detection .....	6
Case Confirmation .....	11
Subtype Classification .....	12
Treatment .....	17
References .....	21
Order Form .....	27
Reprint Information, Questions & Correspondences .....	Inside Back Cover

# Abstract

**Objective:** To develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism.

**Participants:** The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, one methodologist, and a medical writer. The Task Force received no corporate funding or remuneration.

**Evidence:** Systematic reviews of available evidence were used to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group criteria to describe both the quality of evidence and the strength of recommendations. We used ‘recommend’ for strong recommendations and ‘suggest’ for weak recommendations.

**Consensus Process:** Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and multiple e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society’s CGS, Clinical Affairs Core Committee (CACC), and Council. The version approved by the CGS and CACC was placed on The Endocrine Society’s Web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes.

**Conclusions:** We recommend case detection of primary aldosteronism be sought in higher risk groups of hypertensive patients and those with hypokalemia by determining the aldosterone-renin ratio under standard conditions, and that the condition be confirmed/excluded by one of four commonly used confirmatory tests. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography (CT) as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend the presence of a unilateral form of primary aldosteronism should be established/excluded by bilateral adrenal venous sampling by an experienced radiologist and, where present, optimally treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia, or those unsuitable for surgery, optimally be treated medically by mineralocorticoid receptor antagonists.

*(J Clin Endocrinol Metab 93: 3266–3281, 2008)*

---

**Abbreviations:**

APA, aldosterone-producing adenoma; ARR, plasma aldosterone: renin ratio; AVS, adrenal venous sampling; CT, computed tomography; DRC, direct rennin concentration; FST, fludrocortisone suppression testing; GRA, glucocorticoidremediable aldosteronism; IHA, idiopathic hyperaldosteronism; MR, mineralocorticoid receptor; MRI, magnetic resonance imaging; PA, primary aldosteronism; PAC, plasma aldosterone concentration; PRA, plasma rennin activity; SIT, saline infusion test; UAH, unilateral adrenal hyperplasia

## SUMMARY OF RECOMMENDATIONS

### 1.0. CASE DETECTION

1.1. We recommend the case detection of primary aldosteronism (PA) in patient groups with relatively high prevalence of PA. (1| ⊕⊕○○ ) These include patients with Joint National Commission (JNC) stage 2 (>160–179/100–109 mm Hg), stage 3 (>180/110 mm Hg), or drug resistant hypertension; hypertension and spontaneous or diuretic-induced hypokalemia; hypertension with adrenal incidentaloma; or hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (<40 years). We also recommend case detection for all hypertensive first-degree relatives of patients with PA. (1| ⊕○○○ )

1.2. We recommend use of the plasma aldosterone-renin ratio (ARR) to detect cases of PA in these patient groups. (1| ⊕⊕○○ )

### 2.0. CASE CONFIRMATION

2.1. Instead of proceeding directly to subtype classification, we recommend that patients with a positive aldosterone-renin ratio (ARR) undergo testing, by any of four confirmatory tests, to definitively confirm or exclude the diagnosis. (1| ⊕⊕○○ )

### 3.0. SUBTYPE CLASSIFICATION

3.1. We recommend that all patients with PA undergo an adrenal computed tomography (CT) scan as the initial study in subtype testing and to exclude large masses that may represent adrenocortical carcinoma. (1| ⊕⊕○○ )

3.2. We recommend that, when surgical treatment is practicable and desired by the patient, the distinction between unilateral and bilateral adrenal disease be made by adrenal venous sampling (AVS) by an experienced radiologist. (1| ⊕⊕⊕○ )

3.3. In patients with onset of confirmed PA earlier than at 20 years of age and in those who have a family history of PA or of strokes at young age (<40 years), we suggest genetic testing for glucocorticoid-remediable aldosteronism (GRA). (2| ⊕○○○ )

### 4.0. TREATMENT

4.1. We recommend that treatment by unilateral laparoscopic adrenalectomy be offered to patients with documented unilateral PA (i.e., aldosterone-producing adenoma [APA] or unilateral adrenal hyperplasia [UAH]). (1| ⊕⊕○○ ) If a patient is unable or unwilling to undergo surgery, we recommend medical treatment with a mineralocorticoid receptor (MR) antagonist. (1| ⊕⊕○○ )

4.2. In patients with PA due to bilateral adrenal disease, we recommend medical treatment with an MR antagonist (1| ⊕⊕○○ ); we suggest spironolactone as the primary agent with eplerenone as an alternative. (2| ⊕○○○ )

4.3. In patients with GRA, we recommend the use of the lowest dose of glucocorticoid that can normalize blood pressure and serum potassium levels rather than first-line treatment with an MR antagonist. (1| ⊕○○○ )

---

## METHOD OF DEVELOPMENT OF EVIDENCE-BASED GUIDELINES

---

The Clinical Guidelines Subcommittee of The Endocrine Society deemed detection, diagnosis, and treatment of patients with primary aldosteronism (PA) a priority area in need of practice guidelines and appointed a seven-member Task Force to formulate evidence-based recommendations. The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in development and implementation of evidence-based guidelines (1).

The Task Force used the best available research evidence that members identified to inform the recommendations and consistent language and graphical descriptions of both the strength of a recommendation and the quality of evidence. In terms of the strength of the recommendation, strong recommendations use the phrase “we recommend” and the number 1, and weak recommendations use the phrase “we suggest” and the number 2. Cross-filled circles indicate the quality of the evidence, such that ⊕○○○ denotes very low quality evidence; ⊕⊕○○, low quality; ⊕⊕⊕○, moderate quality; and ⊕⊕⊕⊕, high quality. The Task Force has confidence that patients who receive care according to the strong recommendations will derive, on average, more good than harm. Weak recommendations require more careful consideration of the patient’s circumstances, values and preferences to determine the best course of action. A detailed description of this grading scheme has been published elsewhere (2).

Linked to each *recommendation* is a description of the *evidence*, *values* that panelists considered in making the recommendation (when making these explicit was necessary), and *remarks*, a section in which panelists offer technical suggestions for testing conditions, dosing and monitoring. These technical comments reflect the best available evidence applied to a typical patient. Often, this evidence comes from the unsystematic observations of the panelists and should, therefore, be considered suggestions.

---

## DEFINITION AND CLINICAL SIGNIFICANCE OF PRIMARY ALDOSTERONISM

---

### *What is primary aldosteronism?*

Primary aldosteronism (PA) is a group of disorders in which aldosterone production is inappropriately high, relatively autonomous, and non-suppressible by sodium loading. Such inappropriate production of aldosterone causes cardiovascular damage, suppression of plasma renin, hypertension, sodium retention, and potassium excretion that if prolonged and severe may lead to hypokalemia. PA is commonly caused by an adrenal adenoma, by unilateral or bilateral adrenal hyperplasia, or in rare cases by the inherited condition of glucocorticoid-remediable aldosteronism (GRA).

### *How common is PA?*

Most experts previously described PA in <1% of patients with mild-to-moderate essential hypertension and had assumed hypokalemia was a *sine qua non* for diagnosis (3–9). Accumulating evidence has challenged these assumptions. Cross-sectional and prospective studies report PA in >10% of hypertensive patients, both in general and in specialty settings (10–18).

### *How frequent is hypokalemia in PA?*

In recent studies, only a minority of patients with PA (9% to 37%) had hypokalemia (19). Thus, normokalemic hypertension constitutes the most common presentation of the disease, with hypokalemia probably present in only the more severe cases. Half the patients with an aldosterone-producing adenoma (APA) and 17% of those with idiopathic hyperaldosteronism (IHA) had serum potassium concentrations <3.5 mmol/L (17, 20). Thus, the presence of hypokalemia has low sensitivity and specificity, and a low positive predictive value for the diagnosis of PA.

### Why is PA important?

This condition is important not only because of its prevalence, but also because PA patients have higher cardiovascular morbidity and mortality than age- and sex-matched patients with essential hypertension and the same degree of blood pressure elevation (21, 22). Furthermore, specific treatments are available that ameliorate the impact of this condition on patient-important outcomes.

## 1.0. CASE DETECTION

1.1. We recommend the case detection of primary aldosteronism (PA) in patient groups with relatively high prevalence of PA (listed in Table 1) (Figure 1). (1 | ⊕⊕⊕⊕ ) These include patients with Joint National Commission (JNC) stage 2 (>160–179/100–109 mm Hg), stage 3 (>180/110 mm Hg), or drug resistant hypertension; hypertension and spontaneous or diuretic-induced hypokalemia; hypertension with adrenal incidentaloma; or hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (<40 years). We also recommend case detection

for all hypertensive first-degree relatives of patients with PA. (1 | ⊕⊕⊕⊕ )

### 1.1.EVIDENCE

Indirect evidence links the detection of PA with improved patient outcomes. There are no clinical trials of screening that measure the impact of this practice on morbidity, mortality, or quality of life outcomes. Patients could potentially be harmed by the work up and treatment (i.e., by withdrawal of antihypertensive medication, invasive vascular examination, adrenalectomy) aimed at vascular protection along with easier and better blood pressure control. There is strong evidence linking improved blood pressure control and reduction in aldosterone levels to improved cardiac and cerebrovascular outcomes (38). Until prospective studies inform us differently, we recommend that all hypertensive first-degree relatives of patients with PA undergo ARR testing.


### 1.1.VALUES

Our recommendation to detect cases of PA places a high value on avoiding the risks associated with missing the diagnosis (and thus forgoing the opportunity of a surgical cure or improved control of

**TABLE 1. Groups with high prevalence of primary aldosteronism**

Patient group	Prevalence
<b>Moderate/severe hypertension</b> The prevalence rates cited here are from Mosso (16). Others have reported similar estimates (18, 23–25). The classification of blood pressure for adults (aged 18 years and older) was based on the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) which establishes three different stages: Stage 1 = SBP 140-159, DBP 90-99; Stage 2 = SBP 160-179, DBP 100–109; Stage 3 = SBP >180, DBP >110 (10). When systolic and diastolic blood pressures were in different categories, the higher category was selected to classify the individual's blood pressure status.	Overall: 6.1% Stage 1 (mild): 2% Stage 2 (moderate): 8% Stage 3 (severe): 13%
<b>Resistant hypertension</b> , defined as SBP >140 and DBP >90 despite treatment with three hypertensive medications. The prevalence rates cited here are from (26–31).	17%–23%
<b>Hypertensive patients with spontaneous or diuretic-induced PA is hypokalemia.</b>	Specific prevalence figures are not available, but more frequently found in this group.
<b>Hypertension with adrenal incidentaloma</b> (32–37), defined as an adrenal mass detected incidentally during imaging performed for extra-adrenal reasons.	Median: 2% (range, 1.1%–10%) One retrospective study that excluded patients with hypokalemia and severe hypertension found aldosterone-producing adenoma in 16 of 1004 subjects (37).





hypertension through specific medical treatment) and a lower value on avoiding the risk of falsely classifying a hypertensive patient as having PA and exposing him or her to additional diagnostic testing.

1.2. We recommend use of the plasma aldosterone:renin ratio (ARR) to detect cases of PA in these patient groups (Figure 1). (1 | ⊕⊕○○)

### 1.2.EVIDENCE

The ARR is currently the most reliable available means of screening for PA. Although valid estimates of test characteristics of the ARR are lacking (mainly due to limitations in the design of studies that have

addressed this issue) (39), numerous studies have demonstrated the ARR to be superior to measurement of potassium or aldosterone (both of which have lower sensitivity) or of renin (which is less specific) in isolation (40–42).

Like all biochemical case detection tests, the ARR is not without false positives and negatives (17, 18, 39, 43–45). **Table 2** documents the effect of medications and conditions on the ARR. The ARR should therefore be regarded as a detection test only, and should be repeated if the initial results are inconclusive or difficult to interpret because of suboptimal sampling conditions (e.g., maintenance of some medications listed in Table 2).

## 1.2. VALUES

Similar values underpin our recommendation to target subjects in groups with documented high prevalence of PA and to test them by ARR. In particular, this recommendation acknowledges the costs currently associated with ARR testing of all patients with essential hypertension. Against this recommendation for selective testing, however, must be weighed the risk of missing or at least delaying the diagnosis of PA in some hypertensive individuals. The consequences of this may include the later development of more severe and resistant hypertension resulting from failure to lower levels of aldosterone or to block its actions. Furthermore, duration of hypertension has been reported by several investigators to be a negative predictor of outcome following unilateral adrenalectomy for aldosterone-producing adenoma (46, 47), suggesting that delays in diagnosis may result in a poorer response to specific treatment once PA is finally diagnosed.

1.2. Remarks—technical aspects required for the correct implementation of recommendation 1.2.

### Testing conditions (Table 3 & 4)

The ARR is most sensitive when used in patients from whom samples are collected in the *morning* after patients have been out of bed for at least 2 hours, usually after they have been *seated* for 5–15 minutes. Ideally, patients

should have unrestricted dietary salt intake prior to testing. In many cases the ARR can be confidently interpreted with knowledge of the effect on the ARR of continued medications or suboptimal conditions of testing, avoiding delay and allowing the patient to proceed directly to confirmatory/exclusion testing. Washout of all interfering antihypertensive medications is feasible in patients with mild hypertension, but is potentially problematic in others, and perhaps unnecessary in that medications with minimal effect on the ARR can be used in their place (Table 2).

### Assay reliability

Although newer techniques are evolving, we prefer to use validated immunometric assays for plasma renin activity (PRA) or direct renin concentration (DRC); PRA takes into account factors (such as estrogen-containing preparations) that affect endogenous substrate levels. Laboratories should use aliquots from human plasma pools, carefully selected to cover the critical range of measurements, rather than the lyophilized controls provided by the manufacturer to monitor intra- and inter-assay reproducibility and long-term stability. Because the ARR is mathematically highly dependent on renin (49), renin assays should be sufficiently sensitive to measure levels as low as 0.2–0.3 ng/mL/h (DRC 2 mU/L) (10, 16). For PRA, but not DRC, sensitivity for levels <1 ng/mL/h can be improved by prolonging the duration of the assay

**TABLE 2. Medications that have minimal effects on plasma aldosterone levels and can be used to control hypertension during case finding and confirmatory testing for primary aldosteronism**

Drug	Class	Usual dose	Comments
Verapamil slow-release	Non-dihydropyridine antagonist calcium channel	90–120 mg twice daily	Use singly or in combination with the other agents listed in this Table.
Hydralazine	Vasodilator	10–12.5 mg twice daily, increasing as required	Commence verapamil slow-release first to prevent reflex tachycardia. Commencement at low doses reduces risk of side effects (including headaches, flushing, and palpitations).
Prazosin hydrochloride	Alpha-adrenergic blocker	0.5–1 mg two to three times daily, increasing required	Monitor for postural hypotension.
Doxazosin mesylate	Alpha-adrenergic blocker	1–2 mg once daily, increasing as required	Monitor for postural hypotension.
Terazosin hydrochloride	Alpha-adrenergic blocker	1–2 mg once daily, increasing as required	Monitor for postural hypotension.

**TABLE 3. Measurement of the aldosterone-renin ratio: a suggested approach**

- A. Preparation for aldosterone-renin ratio (ARR) measurement: agenda
1. Attempt to correct hypokalemia, after measuring plasma potassium in blood collected slowly with a syringe and needle [preferably not a Vacutainer to minimize the risk of spuriously raising potassium], avoiding fist clenching during collection, waiting at least 5 seconds after tourniquet release (if used) to achieve insertion of needle, and ensuring separation of plasma from cells within 30 minutes of collection.
  2. Encourage patient to liberalize (rather than restrict) sodium intake.
  3. Withdraw agents that markedly affect the ARR (48) for at least 4 weeks:
    - a. Spironolactone, eplerenone, amiloride, and triamterene
    - b. Potassium-wasting diuretics
    - c. Products derived from liquorice root (e.g., confectionary licorice, chewing tobacco)
  4. If the results of ARR off the above agents are not diagnostic, and if hypertension can be controlled with relatively non-interfering medications (**see Table 2**), withdraw other medications that may affect the ARR (48) for at least 2 weeks:
    - a. Beta-adrenergic blockers, central alpha-2 agonists (e.g., clonidine, alpha-methyl dopa), nonsteroidal anti-inflammatory drugs
    - b. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, renin inhibitors, dihydropyridine calcium channel antagonists
  5. If necessary to maintain hypertension control, commence other antihypertensive medications that have lesser effects on the ARR (e.g., verapamil slow-release, hydralazine [with verapamil slow-release, to avoid reflex tachycardia], prazosin, doxazosin, terazosin; **see Table 2**).
  6. Establish oral contraceptive (OC) and hormone replacement therapy (HRT) status, as estrogen-containing medications may lower direct renin concentration (DRC) and cause false positive ARR when DRC (rather than plasma renin activity) is measured. Do not withdraw OC unless confident of alternative effective contraception.
- 
- B. Conditions for collection of blood
1. Collect blood mid-morning, after the patient has been up (sitting, standing, or walking) for at least 2 hours and seated for 5-15 minutes.
  2. Collect blood carefully, avoiding stasis and hemolysis (see A.1 above).
  3. Maintain sample at room temperature (and not on ice, as this will promote conversion of inactive to active renin) during delivery to laboratory and prior to centrifugation and rapid freezing of plasma component pending assay.
- 
- C. Factors to take into account when interpreting results (**see Table 4**)
1. Age: in patients aged >65 years, renin can be lowered more than aldosterone by age alone, leading to a raised ARR
  2. Time of day, recent diet, posture, and length of time in that posture
  3. Medications
  4. Method of blood collection, including any difficulty doing so
  5. Level of potassium
  6. Level of creatinine (renal failure can lead to false positive ARR)

incubation phase as suggested by Sealey and Laragh (50). Although most laboratories use radioimmunoassay for plasma and urinary aldosterone, measured levels of standards have been shown to be unacceptably different in some instances (51). Tandem mass spectrometry is increasingly used and has proved to be much more consistent in performance (52).

### Interpretation

There are important and confusing differences between laboratories in the methods and units used to report values of renin and aldosterone. For

aldosterone, 1 ng/dL converts to 27.7 pmol/L in Système International [SI] units. For immunometric methods of directly measuring renin concentration, a PRA level of 1 ng/mL/h (12.8 pmol/L/min in SI units) converts to a DRC of approximately 8.2 mU/L (5.2 ng/L in traditional units) when measured by either the Nichols Institute Diagnostics automated chemiluminescence immunoassay (previously widely used but recently withdrawn) or the Bio-Rad Renin II radioimmunoassay. Because DRC assays are still in evolution, these conversion factors may change. For example, 1 ng/mL/h PRA converts to a

**TABLE 4. Factors that may affect the aldosterone-renin ratio and thus lead to false positive or false negative results**

Factor	Effect on aldosterone levels	Effect on renin levels	Effect on ARR
<b>Medications</b>			
Beta-adrenergic blockers	↓	↓ ↓	↑ (FP)
Central alpha-2 agonists (e.g., clonidine, alpha-methyl dopa)	↓	↓ ↓	↑ (FP)
NSAIDs	↓	↓ ↓	↑ (FP)
K <sup>+</sup> -wasting diuretics	→ ↑	↑ ↑	↓ (FN)
K <sup>+</sup> -sparing diuretics	↑	↑ ↑	↓ (FN)
ACE inhibitors	↓	↑ ↑	↓ (FN)
ARBs	↓	↑ ↑	↓ (FN)
Ca <sup>2+</sup> blockers (DHPs)	→ ↓	↑	↓ (FN)
Renin inhibitors	↓	↓ ↑ *	↑ (FP)*
			↓ (FN)*
<b>Potassium status</b>			
Hypokalemia	↓	→ ↑	↓ (FN)
Potassium loading	↑	→ ↓	↑ (FP)
<b>Dietary sodium</b>			
Sodium restricted	↑	↑ ↑	↓ (FN)
Sodium loaded	↓	↓ ↓	↑ (FP)
<b>Advancing age</b>			
	↓	↓ ↓	↑ (FP)
<b>Other conditions</b>			
Renal impairment	→	↓	↑ (FP)
PHA-2	→	↓	↑ (FP)
Pregnancy	↑	↑ ↑	↓ (FN)
Renovascular HT	↑	↑ ↑	↓ (FN)
Malignant HT	↑	↑ ↑	↓ (FN)

ARR, aldosterone-renin ratio; NSAIDs, non-steroidal anti-inflammatory drugs; K<sup>+</sup>, potassium; ACE, angiotensin converting enzyme; ARBs, angiotensin II type 1 receptor blockers; DHPs, dihydropyridines; PHA-2, pseudohypoaldosteronism type 2 (familial hypertension and hyperkalemia with normal glomerular filtration rate); HT, hypertension; FP, false positive; FN, false negative.

\*Renin inhibitors lower plasma renin activity (PRA), but raise direct active renin concentrations (DRC). This would be expected to result in false positive ARR levels for renin measured as PRA and false negatives for renin measured as DRC.

DRC of approximately 12 mU/L (7.6 ng/L) when measured by the recently introduced and already widely used Diasorin automated chemiluminescence immunoassay. Here, we express aldosterone and PRA levels in conventional units (aldosterone in nanograms per deciliter; plasma renin activity in

nanograms per milliliter per hour) with SI units for aldosterone and DRC (using the 8.2 conversion factor) given in parentheses. Lack of uniformity in diagnostic protocols and assay methods for ARR measurement has been associated with substantial variability in cut-off values used by different groups

ranging from 20 to 100 (68 to 338) (11, 14, 15, 19, 29, 53, 54). Most groups, however, use cut-offs of 20 to 40 (68 to 135) when testing is performed in the morning on a seated ambulatory patient. Table 5 lists ARR cut-off values using some commonly expressed assay units for plasma aldosterone concentration, plasma renin activity, and direct measurement of plasma renin concentration.

Some investigators require elevated aldosterone levels in addition to elevated ARR for a positive screening test for PA (usually aldosterone >15 ng/dL [416 pmol/L]) (55). An alternative approach is to avoid a formal cut-off level for plasma aldosterone, but to recognize that the likelihood of a false positive ARR becomes greater when renin levels are very low (11). Against a formal cut-off level for aldosterone are the findings of several studies. In one study, seated plasma aldosterone levels were <15 ng/dL (<416 pmol/L) in 36% of 74 patients diagnosed with PA after screening positive by ARR defined as >30 (>100) and showing failure of aldosterone to suppress during fludrocortisone suppression testing (FST), and in four of 21 patients found by adrenal venous sampling (AVS) to have unilateral, surgically correctable PA (56). Another study reported plasma aldosterone levels of 9–16 ng/dL (250–440 pmol/L) in 16 of 37 patients diagnosed with PA by FST (16). While it would clearly be desirable to provide firm recommendations for ARR and plasma aldosterone cut-offs, the variability of assays between laboratories and the divided literature to date make it more

prudent to point out relative advantages and disadvantages, leaving clinicians the flexibility to judge for themselves.

## 2.0. CASE CONFIRMATION

2.1. Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR measurement undergo testing, by any of four confirmatory tests, to definitively confirm or exclude the diagnosis (Figure 1). (1 | ⊕⊕○○)

### 2.1.EVIDENCE

The current literature does not identify a gold standard confirmatory test for PA. Test performance has been evaluated only retrospectively, in relatively small series of patients selected with high prior (pre-test) probability of PA, commonly in comparison with other tests rather than towards a conclusive diagnosis of PA.

Some of these limitations are illustrated in the following example. There is empirical evidence that case-control designs for establishing the accuracy of diagnostic tests overestimate their accuracy. Giacchetti et al. (57) used such a design including 61 PA patients (26 with confirmed APA) and 157 patients with essential hypertension. In this context, they found that a post-sodium infusion test with a cut-off value for plasma aldosterone of  $\geq 7$  ng/dL

**TABLE 5. ARR cut-off values, depending on assay and based on whether PAC, PRA, and DRC are measured in conventional or SI units**

	<b>PRA</b> (measured in ng/mL/h)	<b>PRA</b> (measured in pmol/L/min)	<b>DRC<sup>a</sup></b> (measured in mU/L)	<b>DRC<sup>a</sup></b> (measured in ng/L)
<b>PAC</b> (as ng/dL)	20 <b>30<sup>b</sup></b> 40	1.6 2.5 3.1	2.4 3.7 4.9	3.8 5.7 7.7
<b>PAC</b> (as pmol/L)	<b>750<sup>b</sup></b> 1000	60 80	91 122	144 192

ARR, Aldosterone-renin ratio; PAC, plasma aldosterone concentration; PRA, plasma renin activity; DRC, direct renin concentration; SI, Système International.

<sup>a</sup> Values shown are on the basis of a conversion factor of PRA (ng/mL/h) to DRC (mU/L) of 8.2. DRC assays are still in evolution, and in a recently introduced and already commonly used automated DRC assay, the conversion factor is 12 (see text).

<sup>b</sup> The most commonly adopted cut-off values are shown in bold: 30 for PAC and PRA in conventional units (equivalent to 830 when PAC is in SI units) and 750 when PAC is expressed in SI units (equivalent to 27 in conventional units).

showed a sensitivity of 88% and a specificity of 100% when evaluated by ROC curve in the 76 cases with ARR >40 ng/dL per ng/mL/h. In the prospective PAPY study, analysis of sensitivity/specificity in the 317 patients undergoing a saline infusion test (SIT) gave a best aldosterone cut-off value of 6.8 ng/dL. The sensitivity and specificity, however, were moderate (respectively 83% and 75%), reflecting values overlapping between patients with and without disease; use of the aldosterone-cortisol ratio did not improve the accuracy of the test (17, 58).

Four testing procedures (oral sodium loading, saline infusion, fludrocortisone suppression, and captopril challenge) are in common use, and there is currently insufficient direct evidence to recommend one over the others. While it is acknowledged that these tests may differ in terms of sensitivity, specificity, and reliability, the choice of confirmatory test is commonly determined by considerations of cost, patient compliance, laboratory routine, and local expertise (Table 6). It should be noted that confirmatory tests requiring oral or intravenous sodium loading should be administered with caution in patients with uncontrolled hypertension or congestive heart failure. We recommend that the pharmacological agents with minimal or no effects on the renin-angiotensin-aldosterone system shown in Table 2 be utilized to control blood pressure during confirmatory testing.

### 2.1. VALUES

Confirmatory testing places a high value on sparing individuals with false-positive ARR tests costly and intrusive lateralization procedures.

### 2.1. REMARKS

For each of the four confirmatory tests, procedures, interpretations, and concerns are described in Table 6.

## 3.0. SUBTYPE CLASSIFICATION

3.1. We recommend that all patients with PA undergo an adrenal computed tomography (CT) scan as the initial study in subtype testing and to exclude large masses that may represent adrenocortical carcinoma (Figure 1). (1 | ⊕⊕○○)

### 3.1. EVIDENCE

The findings on adrenal CT—normal-appearing adrenals, unilateral macroadenoma (>1 cm), minimal unilateral adrenal limb thickening, unilateral microadenomas (≤1 cm), or bilateral macro- or microadenomas (or a combination of the two)—are used in conjunction with AVS and, if needed, ancillary tests to guide treatment decisions in patients with PA. APA may be visualized as small hypodense nodules (usually <2 cm in diameter) on CT. IHA adrenal glands may be normal on CT or show nodular changes. Aldosterone-producing adrenal carcinomas are almost always >4 cm in diameter, but occasionally smaller, and like most adrenocortical carcinomas have a suspicious imaging phenotype on CT (69).

Adrenal CT has several limitations. Small APAs may be interpreted incorrectly by the radiologist as “IHA” on the basis of CT findings of bilateral nodularity or normal-appearing adrenals. Moreover, apparent adrenal microadenomas may actually represent areas of hyperplasia, and unilateral adrenalectomy would be inappropriate. In addition, nonfunctioning unilateral adrenal macroadenomas are not uncommon, especially in older patients (>40 years) (70) and are indistinguishable from APAs on CT. Unilateral UAH may be visible on CT or the UAH adrenal may appear normal on CT.

In one study, CT contributed to lateralization in only 59 of 111 patients with surgically proven APA; CT detected fewer than 25% of the APAs that were smaller than 1 cm in diameter (62). In another study of 203 patients with PA who were evaluated with both CT and AVS, CT was accurate in only 53% of patients (71). On the basis of CT findings, 42 patients (22%) would have been incorrectly excluded as candidates



**TABLE 6. Primary aldosteronism confirmatory tests**

Confirmatory test	Procedure	Interpretation	Concerns
Oral sodium loading test	Patients should increase their sodium intake to >200 mmol (~6 g) per day for 3 days, verified by 24-hour urine sodium content. Patients should receive adequate slow-release potassium chloride supplementation to maintain plasma potassium in the normal range. Urinary aldosterone is measured in the 24-hour urine collection from the morning of day 3 to the morning of day 4.	PA is unlikely if urinary aldosterone is lower than 10 mcg/24-hr (27.7 nmol/day) in the absence of renal disease where PA may co-exist with lower measured urinary aldosterone levels. Elevated urinary aldosterone excretion (>12 mcg/24-hr [ $>33.3$ nmol/d] at the Mayo Clinic, >14 mcg/24-hr (38.8 nmol/d) at the Cleveland Clinic) makes PA highly likely.	This test should not be performed in patients with severe uncontrolled hypertension, renal insufficiency, cardiac insufficiency, cardiac arrhythmia, or severe hypokalemia. 24-hour urine collection may be inconvenient. Laboratory-specific poor performance of the radio-immunoassay for urinary aldosterone (aldosterone 18-oxo-glucuronide or acid-labile metabolite) may blunt diagnostic accuracy—a problem obviated by the currently available HPLC-tandem mass spectrometry methodology (52). Aldosterone 18-oxo-glucuronide is a renal metabolite, and its excretion may not rise in patients with renal disease.
Saline infusion test	Patients stay in the recumbent position for at least 1 hour before and during the infusion of 2 liters of 0.9% saline i.v. over 4 hours, starting at 8:00–9:30 a.m. Blood samples for renin, aldosterone, cortisol, and plasma potassium are drawn at time zero and after 4 hours, with blood pressure and heart rate monitored throughout the test.	Post-infusion plasma aldosterone levels <5 ng/dL make the diagnosis of PA unlikely, and levels >10 ng/dL are a very probable sign of PA. Values between 5 and 10 ng/dL are indeterminate (57–60).	This test should not be performed in patients with severe uncontrolled hypertension, renal insufficiency, cardiac insufficiency, cardiac arrhythmia, or severe hypokalemia.
Fludrocortisone suppression test	Patients receive 0.1 mg oral fludrocortisone every 6 hours for 4 days, together with slow-release KCl supplements (every 6 hours at doses sufficient to keep plasma K <sup>+</sup> , measured 4 times a day, close to 4.0 mmol/L), slow-release NaCl supplements (30 mmol three times daily with meals) and sufficient dietary salt to maintain a urinary sodium excretion rate of at least 3 mmol/kg body weight. On day 4, plasma aldosterone and PRA are measured at 10 a.m. with the patient in the seated posture, and plasma cortisol is measured at 7 a.m. and 10 a.m.	Upright plasma aldosterone >6 ng/dL on day 4 at 10 a.m. confirms PA, provided PRA is <1 ng/mL/h and plasma cortisol concentration is lower than the value obtained at 7 a.m. (to exclude a confounding ACTH effect) (42, 43, 56, 61–63).	While some centers (10, 16) conduct this test in the outpatient setting (provided that patients are able to attend frequently to monitor their potassium), in other centers several days of hospitalization are customary. Most of the data available come from the Brisbane group (42, 43, 56, 61–63) who have established, on the basis of a very large series of patients, a cut-off of a plasma aldosterone concentration of 6 ng/dL at 10 a.m. in an ambulatory patient on day 4. Proponents of the FST argue that (1) it is the most sensitive for confirming PA, (2) it is a less intrusive method of sodium loading than SIT and therefore less likely to provoke non-renin-dependent alterations of aldosterone levels, (3) it allows for the potentially confounding effects of potassium to be controlled, and for ACTH (via cortisol) to be monitored and detected, and (4) it is safe when performed by experienced hands.
Captopril challenge test	Patients receive 25–50 mg of captopril orally after sitting or standing for at least 1 hour. Blood samples are drawn for measurement of PRA, plasma aldosterone, and cortisol at time zero and at 1 or 2 hours after challenge, with the patient remaining seated during this period.	Plasma aldosterone is normally suppressed by captopril (>30%). In patients with PA it remains elevated and PRA remains suppressed. Differences may be seen between patients with APA and those with IHA, in that some decrease of aldosterone levels is occasionally seen in IHA (23, 64–66).	There are reports of a substantial number of false negative or equivocal results (67, 68).

for adrenalectomy, and 48 (25%) might have had unnecessary or inappropriate surgery (71). In a recent study, AVS was performed in 41 patients with PA, and concordance between CT and AVS was only 54% (72). Therefore, AVS is essential to direct appropriate therapy in patients with PA who seek a potential surgical cure. CT is particularly useful, however, for detecting larger lesions (e.g., >2.5 cm) that may warrant consideration for removal based on malignant potential and also for localizing the right adrenal vein as it enters into the inferior vena cava, thus aiding cannulation of the vein during AVS (73, 74).

### 3.1. REMARKS

Magnetic resonance imaging (MRI) has no advantage over CT in subtype evaluation of primary aldosteronism, being more expensive and having less spatial resolution than CT.

**3.2.** We recommend that, when surgical treatment is practicable and desired by the patient, the distinction between unilateral and bilateral adrenal disease be made by AVS by an experienced radiologist (Figure 1). (11 ⊕⊕⊕○)

### 3.2. EVIDENCE

Lateralization of the source of the excessive aldosterone secretion is critical to guide the management of PA. Distinguishing between unilateral and bilateral disease is important because unilateral adrenalectomy in patients with APA or unilateral adrenal hyperplasia (UAH) results in normalization of hypokalemia in all; hypertension is improved in all and cured in 30% to 60% (46, 75, 76). In bilateral IHA and GRA, unilateral or bilateral adrenalectomy seldom corrects the hypertension (77–81), and medical therapy is the treatment of choice (82). Unilateral disease may be treated medically if the patient declines or is not a candidate for surgery.

Imaging cannot reliably visualize microadenomas or distinguish incidentalomas from aldosterone-producing adenomas with confidence (71), making AVS the most accurate means of differentiating unilateral from bilateral forms of PA. AVS is

expensive and invasive, and so it is highly desirable to avoid this test in patients who do not have PA (83). Since ARR testing can be associated with false positives, confirmatory testing should eliminate the potential for patients with false positive ARR to undergo AVS.

The sensitivity and specificity of AVS (95% and 100%, respectively) for detecting unilateral aldosterone excess are superior to that of adrenal CT (78% and 75%, respectively) (62, 71, 72). Importantly, CT has the potential to be frankly misleading by demonstrating unilateral nodules in patients with bilateral disease and thereby to lead to inappropriate surgery.

AVS is the reference standard test to differentiate unilateral (APA or UAH) from bilateral disease (IHA) in patients with PA (62, 71). Although AVS can be a difficult procedure, especially in terms of successfully cannulating the right adrenal vein (which is smaller than the left and usually empties directly into the inferior vena cava rather than the renal vein), the success rate usually improves quickly as the angiographer becomes more experienced. According to a review of 47 reports, the success rate for cannulating the right adrenal vein in 384 patients was 74% (82). With experience, the success rate increased to 90%–96% (71, 73, 74, 84). The addition of rapid intraprocedural measurement of adrenal vein cortisol concentrations has facilitated improved accuracy of catheter placement in AVS (85). Some centers perform AVS in all patients who have the diagnosis of PA (62), and others advocate its selective use (e.g., AVS may not be needed in patients younger than age 40 with solitary unilateral apparent adenoma on CT scan) (71, 86).

At centers with experienced AVS radiologists, the complication rate is 2.5% or lower (71, 73). The risk of adrenal hemorrhage can be minimized by employing a radiologist skilled in the technique, and by avoiding adrenal venography and limiting use of contrast to the smallest amounts necessary to assess the catheter tip position (74). Where there is a clinical suspicion of a pro-coagulant disorder, the risk of thrombo-embolism may be reduced by performing tests for such conditions before the procedure and



administering heparin after the procedure in patients at risk.

### 3.2. VALUES

Our recommendation to pursue AVS in the subtype evaluation of the patient with PA who is a candidate for surgery places a high value on avoiding the risk of an unnecessary unilateral adrenalectomy based on adrenal CT and a relatively low value on avoiding the potential complications of AVS.

### 3.2. REMARKS

A radiologist experienced with and dedicated to AVS is needed to implement this recommendation.

There are three protocols for AVS: a) unstimulated sequential or simultaneous bilateral AVS, b) unstimulated sequential or simultaneous bilateral AVS followed by bolus cosyntropin-stimulated sequential or simultaneous bilateral AVS, and c) continuous cosyntropin infusion with sequential bilateral AVS. Simultaneous bilateral AVS is difficult to perform and is not used at most centers. Many groups advocate the use of continuous cosyntropin infusion during AVS a) to minimize stress-induced fluctuations in aldosterone secretion during nonsimultaneous (sequential) AVS, b) to maximize the gradient in cortisol from adrenal vein to inferior vena cava and thus confirm successful sampling of the adrenal vein, and c) to maximize the secretion of aldosterone from an APA (71, 81, 84, 87) and thus avoid the risk of sampling during a relatively quiescent phase of aldosterone secretion.

The criteria used to determine lateralization of aldosterone hypersecretion depend on whether the sampling is done under cosyntropin administration. Dividing the right and left adrenal vein plasma aldosterone concentrations (PACs) by their respective cortisol concentrations corrects for dilutional effects of the inferior phrenic vein flowing into the left adrenal vein and, if suboptimally sampled, of IVC flow into the right adrenal vein. These are termed “cortisol-corrected aldosterone ratios.” With continuous cosyntropin administration, a cut-off of the cortisol-corrected aldosterone ratio

from high-side to low-side more than 4:1 is used to indicate unilateral aldosterone excess (71); a ratio less than 3:1 is suggestive of bilateral aldosterone hypersecretion (71). With these cut-offs, AVS for detecting unilateral aldosterone hypersecretion (APA or UAH) has a sensitivity of 95% and specificity of 100% (71). Patients with lateralization ratios between 3:1 and 4:1 may have either unilateral or bilateral disease, and the AVS results must be interpreted in conjunction with the clinical setting, CT scan, and ancillary tests.

Some investigators consider a cortisol-corrected aldosterone lateralization ratio (high to low side) of more than 2:1 in the absence of cosyntropin as consistent with unilateral disease (83). Other groups rely primarily on comparing the adrenal vein aldosterone-cortisol ratios to those in a simultaneously collected peripheral venous sample (62). When the aldosterone-cortisol ratio from an adrenal vein is significantly (usually at least 2.5 times) greater than that the peripheral vein (cubital fossa or IVC), and the aldosterone-cortisol ratio in the contralateral adrenal vein is no higher than peripheral (indicating contralateral suppression), the ratio is considered to show lateralization, an indication that unilateral adrenalectomy should cure or improve the hypertension.

#### *Cosyntropin use*

If cosyntropin infusion is not used, AVS should be performed in the morning hours following overnight recumbency. This approach avoids the confounding effects of changes in posture on aldosterone levels in patients with angiotensin II-responsive varieties of PA and takes advantage of the effect of high early morning endogenous ACTH levels on aldosterone production in all subtypes of PA (74).

If cosyntropin infusion is used, it may be continuous or bolus. For continuous cosyntropin, an infusion of 50 µg of cosyntropin per hour is begun 30 minutes before adrenal vein catheterization and continued throughout the procedure (71, 81, 84). The bolus cosyntropin technique involves AVS before and after the intravenous administration of 250 µg of cosyntropin. However, some groups have suggested that when given as a bolus injection and when the

adrenal veins are sampled simultaneously, cosyntropin administration does not improve the diagnostic accuracy of AVS and that cosyntropin may in fact increase secretion from the non-adenomatous gland to a greater degree than from the APA (88).

### *Catheterization*

The adrenal veins are catheterized through the percutaneous femoral vein approach, and the position of the catheter tip is verified by gentle injection of a small amount of nonionic contrast medium and radiographic documentation (73). Blood is obtained from both adrenal veins and a peripheral vein, e.g., cubital fossa or iliac vein, and labeled peripheral and assayed for aldosterone and cortisol concentrations. To be sure there is no cross-contamination, the “peripheral” sample should be obtained from a cubital or iliac vein. The venous sample from the left side typically is obtained with the catheter tip at the junction of the inferior phrenic and left adrenal vein. The right adrenal vein may be especially difficult to catheterize because it is short and enters the IVC at an acute angle (84). The cortisol concentrations from the adrenal veins and peripheral vein are used to confirm successful catheterization. The adrenal/peripheral vein cortisol ratio is typically more than 10:1 with the continuous cosyntropin infusion protocol (71) and more than 3:1 without the use of cosyntropin (43).

### *Unsuccessful adrenal venous sampling*

When both adrenal veins are not successfully catheterized, the clinician may (1) repeat AVS; (2) treat the patient with MR antagonist; (3) consider surgery based the findings of other studies (e.g., adrenal CT). Additional studies that may guide the clinician in this setting include posture stimulation test and iodocholesterol scintigraphy.

**Posture stimulation test.** In patients with unsuccessful AVS and with a CT scan showing a unilateral adrenal mass, some experts use the posture stimulation test. This test, developed in the 1970s, was based on the finding that the PAC in patients with APA showed diurnal variation and was relatively unaffected by changes in angiotensin II levels, whereas IHA was characterized by enhanced sensitivity to a small change in angiotensin II that occurred with standing

(89). In a review of 16 published reports, the accuracy of the posture stimulation test was 85% in 246 patients with surgically verified APA (82). The lack of accuracy is explained by the fact that some APAs are sensitive to angiotensin II and some patients with IHA have diurnal variation in aldosterone secretion (90). Thus, the posture stimulation test—particularly if it shows lack of responsiveness (consistent with angiotensin II-unresponsive APA or familial hyperaldosteronism type I (FH-I), with the latter readily confirmed or excluded by genetic testing)—may serve an ancillary role, for example, in those patients for whom AVS was unsuccessful and CT shows a unilateral adrenal mass (91, 92).

**Iodocholesterol scintigraphy.** [131I]-19-iodocholesterol scintigraphy was first used in the early 1970s (93), and an improved agent, [6β-131I]iodomethyl-19-norcholesterol (NP-59), was introduced in 1977 (94). The NP-59 scan, performed with dexamethasone suppression, had the putative advantage of correlating function with anatomical abnormalities. However, the sensitivity of this test depends heavily on the size of the adenoma (95, 96). Because tracer uptake was poor in adenomas smaller than 1.5 cm in diameter, this method often is not helpful in interpreting micronodular findings obtained with high-resolution CT (97) and rarely plays a role in subtype evaluation. Currently it is no longer used in most centers.

**18-Hydroxycorticosterone levels.** 18-Hydroxycorticosterone (18-OHB) is formed by 18-hydroxylation of corticosterone. Patients with APA generally have recumbent plasma 18-OHB levels greater than 100 ng/dL at 8:00 a.m., whereas patients with IHA have levels that are usually less than 100 ng/dL (98). However, this test lacks the accuracy needed to guide the clinician in the subtype evaluation of PA (82).

**3.3.** In patients with onset of confirmed PA earlier than at 20 years of age and in those who have a family history of PA or of strokes at young age, we suggest genetic testing for GRA (Figure 1). (2 | ⊕○○○ )

### 3.3.EVIDENCE

#### Testing for familial forms of PA: FH-I [GRA]

The FH-I syndrome is inherited in an autosomal dominant fashion and is responsible for fewer than 1% of cases of PA (99). GRA presentation is highly variable, with some patients presenting with normal blood pressure and some characterized by aldosterone excess, suppressed PRA, and hypertension of early onset that is usually severe and refractory to conventional antihypertensive therapies.

Some studies suggest a high pretest probability for GRA in children or young adults with severe or resistant hypertension and a positive family history of early onset hypertension and/or premature hemorrhagic stroke (100, 101). In the study by Dluhy and colleagues (100), 50% of children under 18 years of age with GRA had moderate or severe hypertension (blood pressure >99th percentile for age and sex) at diagnosis. Moreover, Litchfield et al. (101) reported in 376 patients from 27 genetically proven GRA pedigrees that 48% of all GRA pedigrees and 18% of all GRA patients had cerebrovascular complications, with the mean age at the time of the initial event being  $32 \pm 11.3$  years. Seventy percent of events were hemorrhagic strokes with an overall case fatality rate of 61% (101). The study design used in these reports does not allow estimation of the yield of new GRA patients that case detection could have in such populations.

Genetic testing by either Southern blot (102) or long polymerase chain reaction (103) techniques is sensitive and specific for GRA and obviates the need to measure the urinary levels of 18-oxocortisol and 18-hydroxy-cortisol or to perform dexamethasone suppression testing, both of which may be misleading (104). Genetic testing for GRA should be considered for PA patients with a family history of PA or of strokes at a young age (101, 105), or with an onset at a young age (e.g., <20 years).

#### Testing for familial forms of PA: FH-II

FH-II is an autosomal dominant disorder and possibly genetically heterogeneous (106). Unlike FH-I, the hyperaldosteronism in FH type II does not suppress

with dexamethasone, and GRA mutation testing is negative (107). FH-II families may have APA, IHA, or both and are clinically indistinguishable from patients with apparent nonfamilial PA (108). Although FH-II is more common than FH-I, accounting for at least 7% of patients with PA in one series, its prevalence is unknown (108). The molecular basis for FH-II is unclear, although several linkage analyses have shown an association with chromosomal region 7p22 (106, 109).

Finally, aldosterone-producing adenoma may rarely but on occasion be seen in multiple endocrine neoplasia type 1.

## 4.0. TREATMENT

4.1. We recommend that unilateral laparoscopic adrenalectomy be offered to patients with documented unilateral PA (i.e., APA or UAH) (Figure 1). (1| ⊕⊕○○ ) If a patient is unable or unwilling to undergo surgery, we recommend medical treatment with an mineralocorticoid receptor antagonist (Figure 1). (1| ⊕⊕○○ )

### 4.1.EVIDENCE

Unilateral laparoscopic adrenalectomy is used in patients with unilateral PA because blood pressure and serum potassium concentrations improve in nearly 100% of patients postoperatively (76, 110–114). Hypertension is cured (defined as BP <140/90 mm Hg without the aid of antihypertensive drugs) in about 50% (range 35%–60%) of patients with APA after unilateral adrenalectomy (75, 110), with a ‘cure’ rate as high as 56%–77% when the cure threshold was blood pressure <160/95 mm Hg (46, 115, 116). There is no high quality evidence linking adrenalectomy with improved quality of life, morbidity, or mortality as studies of this nature have not, to our knowledge, been published.

Factors associated with resolution of hypertension in the post-operative period include having one or no first-degree relative with hypertension and pre-operative use of two or fewer antihypertensive drugs

(76). Other factors have been reported to predict cure, but have only been evaluated by univariate analysis or when the cut-off for blood pressure resolution was <160/95 mm Hg (46, 110, 113): duration of hypertension <5 years (46, 47, 75, 76), higher PAC:PRA ratio preoperatively (75, 76), higher urinary aldosterone secretion (75, 76), or positive pre-operative response to spironolactone (75, 111). The most common reasons for persistently increased blood pressure after adrenalectomy are coexistent hypertension of unknown cause (46, 76) and older age and/or longer duration of hypertension.

As compared with open adrenalectomy, laparoscopic adrenalectomy is associated with shorter hospital stays and fewer complications (112, 117, 118). Because AVS is able to identify only which gland (and not which part of the gland) is overproducing aldosterone, partial adrenalectomy (removal of an adenoma leaving the remaining adrenal intact) may result in persistent hypertension; continued elevation of PAC is found in up to 10% of patients with unilateral APA, and 27% of extirpated adrenal glands are found to contain multiple nodules (119).

Medical management is recommended for patients who do not undergo surgery. In a retrospective study of 24 patients with APA who were treated for 5 years with spironolactone or amiloride, systolic and diastolic BP decreased from an average of 175/106 to 129/79 mm Hg (120) with 83% of these patients requiring additional antihypertensive medication to achieve this result. Furthermore, several of the patients experienced side effects from the spironolactone therapy including breast tenderness (54%), breast engorgement (33%), muscle cramps (29%), and decreased libido (13%). In the long-term, adrenalectomy is more cost-effective than lifelong medical therapy for patients with unilateral primary aldosteronism (121).

Therefore, because unilateral laparoscopic adrenalectomy can either eliminate the need for medication or reduce medication-related side effects, it is the preferred procedure for the treatment of unilateral disease in patients with PA.

#### 4.1. VALUES

Our recommendation to subject patients with unilateral adrenal disease to laparoscopic adrenalectomy in preference to other methods of treatment places a high value on reduction of blood pressure and/or the number of medications necessary to control blood pressure, on normalization of endogenous aldosterone secretion, and on the resolution of hypokalemia. This benefit is far greater than the risks of surgery and post-operative management, which are extremely low.

#### 4.1. REMARKS

This recommendation requires the availability of a surgeon experienced in laparoscopic adrenalectomy.

##### *Preoperative management*

In the patient scheduled for surgery both hypertension and hypokalemia should be well controlled preoperatively. Obtaining such control may require a delay in surgery and the addition of an MR antagonist.

##### *Postoperative management*

Plasma aldosterone and renin activity levels should be measured shortly after surgery as an early indication of biochemical response (114), and on postoperative day 1 potassium supplementation should be withdrawn, spironolactone discontinued, and antihypertensive therapy reduced, if appropriate (122).

Postoperative intravenous fluids should be normal saline without potassium chloride unless serum potassium levels remain very low (i.e., <3.0 mmol/L), and during the first few weeks after surgery a generous sodium diet should be recommended to avoid the hyperkalemia that can develop from hypoaldosteronism due to chronic contralateral adrenal gland suppression (122). In rare instances, temporary fludrocortisone therapy may be required.

Blood pressure typically normalizes or shows maximum improvement in 1–6 months after unilateral adrenalectomy for unilateral APA, but can continue to fall for up to 1 year in some patients. Some investigators have employed postoperative fludrocortisone suppression testing (performed at least 3 months after surgery to permit recovery of the

contralateral gland) to assess whether the PA has been cured from a biochemical perspective (123).

4.2. In patients with PA due to bilateral adrenal disease, we recommend medical treatment with an MR antagonist (1 | ⊕⊕○○); we suggest spironolactone as the primary agent with eplerenone as an alternative. (2 | ⊕○○○) (Figure 1)

#### 4.2.EVIDENCE

Bilateral adrenal disease includes idiopathic adrenal hyperplasia, bilateral APA, and GRA. In 99 surgically treated patients with IHA reported in the literature, the hypertension cure rate was only 19% after unilateral or bilateral adrenalectomy (77-81). No randomized placebo-controlled trials have evaluated the relative efficacy of drugs in the treatment of PA. However, the pathophysiology of PA due to bilateral adrenal hyperplasia and longstanding clinical experience suggest several pharmacological targets.

##### *MR antagonists*

MR antagonists appear to be effective at controlling blood pressure and to provide blood pressure-independent target organ protection.

##### *Spironolactone*

For more than 4 decades, the MR antagonist spironolactone has been the agent of choice in the medical treatment of PA. Several observational studies in patients with IHA (combined N=122) have reported a mean reduction in systolic blood pressure of 25% and diastolic blood pressure of 22% in response to spironolactone 50–400 mg per day for 1 to 96 months (124-130). In a study of 28 hypertensive subjects with an ARR >750 pmol/l (27 ng/dl) per ng/mL per hour who failed to suppress their PAC after salt loading and without evidence of adenoma on adrenal CT scan, spironolactone therapy (25–50 mg/day) reduced the need for antihypertensive drugs by -0.5 (from a mean of 2.3 to 1.8 drugs) drugs, as well as reducing systolic blood pressure by -15 mm Hg (from a mean of 161 to 146 mm Hg) and diastolic blood pressure by -8 mm Hg (from a mean of 91 to 83 mm Hg); 48% of subjects achieved a blood pressure <140/90 mm Hg, and about half were able to be

managed with spironolactone monotherapy (131). The dose of spironolactone employed in that study was much lower than previously considered necessary for the treatment of PA.

The incidence of gynecomastia with spironolactone therapy is dose-related, with one study reporting an incidence after 6 months of 6.9% at a dose <50 mg per day and 52% at a dose >150 mg per day (132). The exact incidence of menstrual disturbances in premenopausal women with spironolactone therapy is unknown. Where available, canrenone (an active metabolite of spironolactone) or potassium canrenoate, its open E-ring water soluble congener, might be considered, in that they possibly have fewer sex steroid-related side effects. In addition, a small dose of a thiazide diuretic, triamterine, or amiloride can be added to attempt to avoid a higher dose of spironolactone, which may cause side effects.

##### *Eplerenone*

Eplerenone is a newer, selective MR antagonist without anti-androgen and progesterone agonist effects (133), thus reducing the rate of adverse endocrine side effects. It has been approved for the treatment of primary (essential) hypertension (134, 135) in the United States and Japan, and for heart failure after myocardial infarction (136) in the United States and a number of other countries. Eplerenone has 60% of the MR antagonist potency of spironolactone; its better tolerability profile needs to be balanced against its higher cost and the lack of current clinical trial evidence for its use in PA. Reflecting its shorter half-life, eplerenone should be given twice daily for optimal effect.

##### *Other agents*

Upregulation of distal tubular sodium epithelial channel activity is a major mechanism whereby aldosterone exerts its actions on sodium and potassium handling. Of the available epithelial sodium channel antagonists (amiloride and triamterene), amiloride has been the most studied as a mode of treatment for PA. Although less efficacious than spironolactone, amiloride may be useful (28, 137). Being a potassium-sparing diuretic, amiloride can ameliorate both hypertension and hypokalemia



in patients with PA and is generally well tolerated, lacking the sex steroid-related side effects of spironolactone, but without the beneficial effects on endothelial function (138, 139).

Calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers have been evaluated in very few patients with PA, and in general they are antihypertensive without a major effect on aldosterone excess. Supportive studies are small and methodologically weak, and have not measured patient-important outcomes. Aldosterone synthase inhibitors may play a role in the future.

#### 4.2. VALUES

This recommendation places a relatively higher value on reduction of blood pressure normalization of serum potassium concentrations and abrogation of the vascular, cardiac, and renal effects of aldosterone with the minimum number of pharmacological agents, and a relatively lower value on side effects such as gynecomastia and erectile dysfunction in men and menstrual irregularities in women. Eplerenone, given its selectivity and despite its cost, is an alternative if the side effects of spironolactone prove difficult to tolerate.

#### 4.2. REMARKS

The starting dose for spironolactone should be 12.5 to 25 mg daily in a single dose. The lowest effective dose should be found by very gradually titrating upward if necessary to a maximum dose of 100 mg per day. The starting dose for eplerenone is 25 mg once or twice daily. In patients with stage III chronic kidney disease (i.e., GFR <60 mL/min/1.73m<sup>2</sup>), spironolactone and eplerenone may be used with caution because of the risk of hyperkalemia, but MR antagonists should be avoided in those with stage IV disease.

**4.3.** In patients with GRA, we recommend the use of the lowest dose of glucocorticoid that can normalize blood pressure and potassium levels rather than first-line treatment with an MR antagonist (Figure 1). (1 | ⊕○○○)

#### 4.3. EVIDENCE

GRA should be treated medically with a glucocorticoid to partially suppress pituitary ACTH secretion. We recommend use of a synthetic glucocorticoid that is longer acting than hydrocortisone, such as dexamethasone or prednisone, to suppress ACTH secretion. Ideally, the glucocorticoid should be taken at bedtime to suppress the early morning ACTH surge. Plasma renin activity and aldosterone concentrations may be helpful in assessing the effectiveness of treatment and the prevention of overtreatment.

Over-treatment with exogenous steroids must be avoided; iatrogenic Cushing's syndrome and impaired linear growth in children have resulted from such overdosing (100). In general, the lowest possible dose of glucocorticoid that normalizes blood pressure and/or serum potassium concentration should be used (74). Treatment with a glucocorticoid may not always normalize blood pressure, and addition of an MR antagonist should be considered in these cases.

The use of eplerenone may be preferred in the case of affected children, in whom there may be concerns with respect to growth retardation and anti-androgenic effects of glucocorticoids and spironolactone, respectively.

#### 4.3. VALUES

The treatment of GRA places a high value on preventing the potential consequences of hyperaldosteronism and a lower value on the possible side effects of chronic glucocorticoid administration.

#### 4.3. REMARKS

The starting dose of dexamethasone in adults is 0.125 to 0.25 mg daily. The starting dose of prednisone is 2.5 to 5 mg daily. For each, treatment is usually administered at bedtime.

# References

1. **Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW, Jr., Zaza S** 2004 Grading quality of evidence and strength of recommendations. *BMJ* 328:1490
2. **Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM** 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. *J Clin Endocrinol Metab* 93:666–73
3. **Andersen GS, Toftdahl DB, Lund JO, Strandgaard S, Nielsen PE** 1988 The incidence rate of pheochromocytoma and Conn's syndrome in Denmark, 1977-1981. *J Hum Hypertens* 2:187–9
4. **Berglund G, Andersson O, Wilhelmsen L** 1976 Prevalence of primary and secondary hypertension: studies in a random population sample. *Br Med J* 2:554–6
5. **Fishman LM, Kuchel O, Liddle GW, Michelakis AM, Gordon RD, Chick WT** 1968 Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. *JAMA* 205:497–502
6. **Kaplan NM** 1967 Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. *Ann Intern Med* 66:1079-90
7. **Streeten DH, Tomycz N, Anderson GH** 1979 Reliability of screening methods for the diagnosis of primary aldosteronism. *Am J Med* 67:403–13
8. **Tucker RM, Labarthe DR** 1977 Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. *Mayo Clin Proc* 52:549–5
9. **Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW** 1987 Secondary hypertension in a blood pressure clinic. *Arch Intern Med* 147:1289–93
10. **Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J** 2000 Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. *J Clin Endocrinol Metab* 85:1863–7
11. **Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC** 1994 High incidence of primary aldosteronism in 199 patients referred with hypertension. *Clin Exp Pharmacol Physiol* 21:315–8
12. **Grim CE, Weinberger MH, Higgins JT, Kramer NJ** 1977 Diagnosis of secondary forms of hypertension. A comprehensive protocol. *JAMA* 237:1331–5
13. **Hamlet SM, Tunny TJ, Woodland E, Gordon RD** 1985 Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism? *Clin Exp Pharmacol Physiol* 12:249–52
14. **Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM** 2000 High prevalence of primary aldosteronism in the Tayside hypertension clinic population. *J Hum Hypertens* 14:311–5
15. **Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF, Jr.** 2000 Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. *J Clin Endocrinol Metab* 85:2854–9
16. **Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE** 2003 Primary aldosteronism and hypertensive disease. *Hypertension* 42:161–5
17. **Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F** 2006 A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol* 48:2293–300
18. **Schwartz GL, Turner ST** 2005 Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. *Clin Chem* 51:386–94
19. **Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF, Jr.** 2004 Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. *J Clin Endocrinol Metab* 89:1045–50
20. **Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F** 2006 Renal damage in primary aldosteronism: results of the PAPY Study. *Hypertension* 48:232–8
21. **Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ** 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. *J Am Coll Cardiol* 45:1243–8
22. **Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH** 2005 Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. *J Clin Endocrinol Metab* 90:5070–6
23. **Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F** 2002 High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. *Am J Hypertens* 15:896–902

24. **Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J, Jr.** 2003 Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. *J Hum Hypertens* 17:349–52
25. **Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR** 2006 Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. *J Hum Hypertens* 20:129–36
26. **Benchetrit S, Bernheim J, Podjarny E** 2002 Normokalemic hyperaldosteronism in patients with resistant hypertension. *Isr Med Assoc J* 4:17–20
27. **Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P** 2002 Hyperaldosteronism among black and white subjects with resistant hypertension. *Hypertension* 40:892–6
28. **Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP** 2004 Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. *J Hypertens* 22:2217–26
29. **Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC** 2001 Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. *Am J Kidney Dis* 37:699–705
30. **Goodfriend TL, Calhoun DA** 2004 Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. *Hypertension* 43:518–24
31. **Calhoun DA, Nishizaka MK, Zaman MA, Harding SM** 2004 Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. *Chest* 125:112–7
32. **Aso Y, Homma Y** 1992 A survey on incidental adrenal tumors in Japan. *J Urol* 147:1478–81
33. **Barzon L, Sonino N, Fallo F, Palu G, Boscaro M** 2003 Prevalence and natural history of adrenal incidentalomas. *Eur J Endocrinol* 149:273–85
34. **Bulow B, Ahren B** 2002 Adrenal incidentaloma—experience of a standardized diagnostic programme in the Swedish prospective study. *J Intern Med* 252:239–46
35. **Caplan RH, Strutt PJ, Wickus GG** 1994 Subclinical hormone secretion by incidentally discovered adrenal masses. *Arch Surg* 129:291–6
36. **Kim HY, Kim SG, Lee KW, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS** 2005 Clinical study of adrenal incidentaloma in Korea. *Korean J Intern Med* 20:303–9
37. **Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A** 2000 A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. *J Clin Endocrinol Metab* 85:637–44
38. **Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC** 1996 Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. *Hypertension* 27:1039–45
39. **Montori VM, Young WF, Jr.** 2002 Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. *Endocrinol Metab Clin North Am* 31:619–32, xi
40. **Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiya T** 1981 A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. *Arch Intern Med* 141:1589–93
41. **McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S** 1991 Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. *J Clin Endocrinol Metab* 73:952–7
42. **Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM** 2003 High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. *J Hypertens* 21:2149–57
43. **Gordon RD** 1995 Primary aldosteronism. *J Endocrinol Invest* 18:495–511
44. **Stowasser M, Gordon RD** 2004 The aldosterone-renin ratio for screening for primary aldosteronism. *The Endocrinologist* 14:267–76
45. **Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K** 2003 Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. *J Clin Endocrinol Metab* 88:2489–94
46. **Celen O, O'Brien MJ, Melby JC, Beazley RM** 1996 Factors influencing outcome of surgery for primary aldosteronism. *Arch Surg* 131:646–50
47. **Streeten DH, Anderson GH, Jr., Wagner S** 1990 Effect of age on response of secondary hypertension to specific treatment. *Am J Hypertens* 3:360–5
48. **Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F** 2002 Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. *Hypertension* 40:897–902
49. **Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST** 2001 Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. *Mayo Clin Proc* 76:877–82
50. **Sealey JE, Laragh JH** 1975 Radioimmunoassay of plasma renin activity. *Semin Nucl Med* 5:189–202
51. **Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M** 2006 Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. *Clin Chem* 52:1749–55
52. **Guo T, Taylor RL, Singh RJ, Soldin SJ** 2006 Simultaneous determination of 12 steroids by isotope dilution liquid chromatography-photospray ionization tandem mass spectrometry. *Clin Chim Acta* 372:76–82
53. **Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP** 2005 The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. *J Clin Endocrinol Metab* 90:72–8



54. **Young WE, Jr.** 1997 Primary aldosteronism: update on diagnosis and treatment. *The Endocrinologist* 7:213–21
55. **Young WF** 2007 Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol (Oxf)* 66:607–18
56. **Stowasser M, Gordon RD** 2004 Primary aldosteronism—careful investigation is essential and rewarding. *Mol Cell Endocrinol* 217:33–9
57. **Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F** 2006 Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. *J Hypertens* 24:737–45
58. **Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F** 2007 Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. *J Hypertens* 25:1433–42
59. **Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE** 1984 Further evaluation of saline infusion for the diagnosis of primary aldosteronism. *Hypertension* 6:717–23
60. **Kem DC, Weinberger MH, Mayes DM, Nugent CA** 1971 Saline suppression of plasma aldosterone in hypertension. *Arch Intern Med* 128:380–6
61. **Gordon RD** 1994 Mineralocorticoid hypertension. *Lancet* 344:240–3
62. **Gordon RD** 2001 Diagnostic investigations in primary aldosteronism. In: Zanchetti A (ed) *Clinical medicine series on hypertension*. McGraw-Hill International, Maidenhead, UK; pp 101–111
63. **Gordon RD, Stowasser M, Klemm SA, Tunny TJ** 1994 Primary aldosteronism and other forms of mineralocorticoid hypertension. In: Swales J (ed) *Textbook of hypertension*. Blackwell Scientific, London; pp 865–892
64. **Agharazii M, Douville P, Grose JH, Lebel M** 2001 Captopril suppression versus salt loading in confirming primary aldosteronism. *Hypertension* 37:1440–3
65. **Mantero F, Fallo F, Opocher G, Armanini D, Boscaro M, Scaroni C** 1981 Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. *Clin Sci (Lond)* 61 Suppl 7:289s–293s
66. **Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F** 2007 Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. *Hypertension* 50:424–31
67. **Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA** 1992 Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. *Clin Endocrinol (Oxf)* 36:499–503
68. **Mulatero P, Bertello C, Garrone C, Rossato D, Mengozzi G, Verhovez A, Fallo F, Veglio F** 2007 Captopril test can give misleading results in patients with suspect primary aldosteronism. *Hypertension* 50:e26–7
69. **Young WE, Jr.** 2007 Clinical practice. The incidentally discovered adrenal mass. *N Engl J Med* 356:601–10
70. **Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B** 1995 Incidentally discovered adrenal masses. *Endocr Rev* 16:460–84
71. **Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA** 2004 Role for adrenal venous sampling in primary aldosteronism. *Surgery* 136:1227–35
72. **Nwariaku FE, Miller BS, Auchus R, Holt S, Watumull L, Dolmatch B, Nesbitt S, Vongpatanasin W, Victor R, Wians F, Livingston E, Snyder WH, 3rd** 2006 Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. *Arch Surg* 141:497–502
73. **Daunt N** 2005 Adrenal vein sampling: how to make it quick, easy, and successful. *Radiographics* 25 (suppl 1):S143–58
74. **Stowasser M, Gordon RD** 2001 Familial hyperaldosteronism. *J Steroid Biochem Mol Biol* 78:215–29
75. **Meyer A, Brabant G, Behrend M** 2005 Long-term follow-up after adrenalectomy for primary aldosteronism. *World J Surg* 29:155–9
76. **Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA** 2001 Primary aldosteronism: factors associated with normalization of blood pressure after surgery. *Ann Intern Med* 135:258–61
77. **Baer L, Sommers SC, Krakoff LR, Newton MA, Laragh JH** 1970 Pseudo-primary aldosteronism. An entity distinct from true primary aldosteronism. *Circ Res* 27:203–20
78. **Gunnells JC, Jr., Bath NM, Sode J, Robinson RR** 1967 Primary aldosteronism. *Arch Intern Med* 120:568–74
79. **Priestley JT, Ferris DO, ReMine WH, Woolner LB** 1968 Primary aldosteronism: surgical management and pathologic findings. *Mayo Clin Proc* 43:761–75
80. **Rhamy RK, McCoy RM, Scott HW, Jr., Fishman LM, Michelakis AM, Liddle GW** 1968 Primary aldosteronism: experience with current diagnostic criteria and surgical treatment in fourteen patients. *Ann Surg* 167:718–27
81. **Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ, Yune HY, Wellman H, Donohue JP** 1979 Primary aldosteronism: diagnosis, localization, and treatment. *Ann Intern Med* 90:386–95
82. **Young WE, Jr., Klee GG** 1988 Primary aldosteronism. Diagnostic evaluation. *Endocrinol Metab Clin North Am* 17:367–95
83. **Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC** 2001 Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. *J Clin Endocrinol Metab* 86:1083–90
84. **Doppman JL, Gill JR, Jr.** 1996 Hyperaldosteronism: sampling the adrenal veins. *Radiology* 198:309–12
85. **Mengozzi G, Rossato D, Bertello C, Garrone C, Milan A, Pagni R, Veglio F, Mulatero P** 2007 Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. *Clin Chem* 53:1968–71

86. **Tan YY, Ogilvie JB, Triponez F, Caron NR, Kebebew EK, Clark OH, Duh QY** 2006 Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. *World J Surg* 30:879–85
87. **Carr CE, Cope C, Cohen DL, Fraker DL, Trerotola SO** 2004 Comparison of sequential versus simultaneous methods of adrenal venous sampling. *J Vasc Interv Radiol* 15:1245–50
88. **Rossi GP, Ganzaroli C, Miotto D, De Toni R, Palumbo G, Feltrin GP, Mantero F, Pessina AC** 2006 Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. *J Hypertens* 24:371–9
89. **Ganguly A, Dowdy AJ, Luetscher JA, Melada GA** 1973 Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma. *J Clin Endocrinol Metab* 36:401–4
90. **Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, Klemm SA** 1987 Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. *J Hypertens Suppl* 5:S103–6
91. **Espiner EA, Ross DG, Yandle TG, Richards AM, Hunt PJ** 2003 Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. *J Clin Endocrinol Metab* 88:3637–44
92. **Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, Linehan WM, Doppman JL, Gill Jr JR, Jr.** 2000 Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. *J Clin Endocrinol Metab* 85:4526–33
93. **Conn JW, Morita R, Cohen EL, Beierwaltes WH, McDonald WJ, Herwig KR** 1972 Primary aldosteronism. Photoscanning of tumors after administration of <sup>131</sup>I-19-iodocholesterol. *Arch Intern Med* 129:417–25
94. **Sarkar SD, Cohen EL, Beierwaltes WH, Ice RD, Cooper R, Gold EN** 1977 A new and superior adrenal imaging agent, <sup>131</sup>I-6beta-iodomethyl-19-nor-cholesterol (NP-59): evaluation in humans. *J Clin Endocrinol Metab* 45:353–62
95. **Hogan MJ, McRae J, Schambelan M, Biglieri EG** 1976 Location of aldosterone-producing adenomas with <sup>131</sup>I-19-iodocholesterol. *N Engl J Med* 294:410–4
96. **Nomura K, Kusakabe K, Maki M, Ito Y, Aiba M, Demura H** 1990 Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. *J Clin Endocrinol Metab* 71:825–30
97. **Mansoor GA, Malchoff CD, Arici MH, Karimeddini MK, Whalen GF** 2002 Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-<sup>131</sup> norcholesterol scanning. *Am J Hypertens* 15:459–64
98. **Biglieri EG, Schambelan M** 1979 The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism. *J Clin Endocrinol Metab* 49:87–91
99. **McMahon GT, Dluhy RG** 2004 Glucocorticoid-remediable aldosteronism. *Cardiol Rev* 12:44–8
100. **Dluhy RG, Anderson B, Harlin B, Ingelfinger J, Lifton R** 2001 Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. *J Pediatr* 138:715–20
101. **Litchfield WR, Anderson BE, Weiss RJ, Lifton RP, Dluhy RG** 1998 Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. *Hypertension* 31:445–50
102. **Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM** 1992 A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. *Nature* 355:262–5
103. **Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD** 1995 A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. *Biochem Biophys Res Commun* 207:565–71
104. **Fardella CE, Pinto M, Mosso L, Gomez-Sanchez C, Jalil J, Montero J** 2001 Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. *J Clin Endocrinol Metab* 86:4805–7
105. **Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS** 2001 Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? *J Hum Hypertens* 15:173–6
106. **So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, Stowasser M** 2005 Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. *J Hypertens* 23:1477–84
107. **Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL** 1991 Clinical and pathological diversity of primary aldosteronism, including a new familial variety. *Clin Exp Pharmacol Physiol* 18:283–6
108. **Stowasser M, Gordon RD** 2003 Primary aldosteronism: from genesis to genetics. *Trends Endocrinol Metab* 14:310–7
109. **Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA** 2000 A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). *J Med Genet* 37:831–5
110. **Blumenfeld JD, Sealey JE, Schlüssel Y, Vaughan ED, Jr., Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH** 1994 Diagnosis and treatment of primary hyperaldosteronism. *Ann Intern Med* 121:877–85
111. **Harris DA, Au-Yong I, Basnyat PS, Sadler GP, Wheeler MH** 2003 Review of surgical management of aldosterone secreting tumours of the adrenal cortex. *Eur J Surg Oncol* 29:467–74
112. **Rossi H, Kim A, Prinz RA** 2002 Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. *Am Surg* 68:253–6; discussion 256–7
113. **Stowasser M, Klemm SA, Tunny TJ, Storie WJ, Rutherford JC, Gordon RD** 1994 Response to unilateral adrenalectomy for aldosterone-producing adenoma: effect

- of potassium levels and angiotensin responsiveness. *Clin Exp Pharmacol Physiol* 21:319–22
114. **Young WE, Jr.** 2003 Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. *Endocrinology* 144:2208–13
  115. **Lo CY, Tam PC, Kung AW, Lam KS, Wong J** 1996 Primary aldosteronism. Results of surgical treatment. *Ann Surg* 224:125–30
  116. **Proye CA, Mulliez EA, Carnaille BM, Lecomte-Houcke M, Decoux M, Wemeau JL, Lefebvre J, Racadot A, Ernst O, Huglo D, Carre A** 1998 Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? *Surgery* 124:1128–33
  117. **Jacobsen NE, Campbell JB, Hobart MG** 2003 Laparoscopic versus open adrenalectomy for surgical adrenal disease. *Can J Urol* 10:1995–9
  118. **Rutherford JC, Stowasser M, Tunny TJ, Klemm SA, Gordon RD** 1996 Laparoscopic adrenalectomy. *World J Surg* 20:758–60; discussion 761
  119. **Ishidoya S, Ito A, Sakai K, Satoh M, Chiba Y, Sato F, Arai Y** 2005 Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. *J Urol* 174:40–3
  120. **Ghose RP, Hall PM, Bravo EL** 1999 Medical management of aldosterone-producing adenomas. *Ann Intern Med* 131:105–8
  121. **Sywak M, Pasiaka JL** 2002 Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. *Br J Surg* 89:1587–93
  122. **Mattsson C, Young WE, Jr.** 2006 Primary aldosteronism: diagnostic and treatment strategies. *Nat Clin Pract Nephrol* 2:198–208
  123. **Rutherford JC, Taylor WL, Stowasser M, Gordon RD** 1998 Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. *World J Surg* 22:1243–5
  124. **Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF, Robertson JI** 1972 Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. *Br Med J* 2:729–34
  125. **Crane MG, Harris JJ** 1970 Effect of spironolactone in hypertensive patients. *Am J Med Sci* 260:311–30
  126. **Ganguly A, Luetscher JA** 1976 Spironolactone therapy in primary aldosteronism: diagnostic and therapeutic implications. In: Sambhi MP (ed) *Systemic effects of antihypertensive agents*. Stratton, New York; pp 383–392
  127. **Helber A, Wambach G, Hummerich W, Bonner G, Meurer KA, Kaufmann W** 1980 Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. *Klin Wochenschr* 58:439–47
  128. **Kater CE, Biglieri EG, Schambelan M, Arteaga E** 1983 Studies of impaired aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism. *Hypertension* 5:V115–21
  129. **Kremer D, Beevers DG, Brown JJ, Davies DL, Ferriss JB, Fraser R, Lever AF, Robertson JI** 1973 Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes. *Clin Sci Mol Med Suppl* 45 Suppl 1:213s–8
  130. **Wambach G, Helber A, Bonner G, Hummerich W, Meurer KA, Kaufmann W** 1980 [Spironolactone in essential hypertension associated with abnormal aldosterone regulation and in Conn's syndrome (author's transl)]. *Dtsch Med Wochenschr* 105:647–51
  131. **Lim PO, Jung RT, MacDonald TM** 1999 Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. *Br J Clin Pharmacol* 48:756–60
  132. **Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Menard J** 1987 Efficacy and tolerance of spironolactone in essential hypertension. *Am J Cardiol* 60:820–5
  133. **de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J, et al.** 1987 Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. *J Pharmacol Exp Ther* 240:650–6
  134. **Burgess ED, Lacourciere Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S, Roniker B, Maurath C** 2003 Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. *Clin Ther* 25:2388–404
  135. **Weinberger MH, Roniker B, Krause SL, Weiss RJ** 2002 Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. *Am J Hypertens* 15:709–16
  136. **Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurlley S, Kleiman J, Gatlin M** 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 348:1309–21
  137. **Lim PO, Young WE, MacDonald TM** 2001 A review of the medical treatment of primary aldosteronism. *J Hypertens* 19:353–61
  138. **Farquharson CA, Struthers AD** 2000 Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. *Circulation* 101:594–7
  139. **Farquharson CA, Struthers AD** 2002 Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. *Heart* 88:475–80

# Acknowledgments

In addition to the members of the Task Force, there have been a number of people whose contribution to these guidelines has been invaluable. First, we would like to thank Dr. Robert Vigersky, the members of the Clinical Guidelines Subcommittee, the Clinical Affairs Core Committee, and the Council of The Endocrine Society for their careful reading of and very useful suggestions for improving the guidelines. Second, we thank the members of The Endocrine Society at large for their input when the draft guidelines were posted on the Society's website; all the responses received were considered by the authors, and many incorporated. Third, we thank the members of our sister societies around the world for their enthusiastic involvement in reading the draft guidelines, and in offering their support for this publication. Fourth, we thank Lisa Marlow of The Endocrine Society, who has provided first-class administrative and logistic back-up, without which such a geographically disperse task force would have faced considerable difficulty in operating. Last, but very much not least, the authors are indebted to Dr. Patricia A. Stephens, medical writer, for her unfailing patience, her meticulous checking of both text and references, and most importantly her ability to meld half a dozen disparate writing styles into a seamless whole.

## Financial Disclosure of Task Force

**John W. Funder, MD, PhD** (chair)—Financial or Business/Organizational Interests: Schering-Plough, Daiichi-Sankyo, Pfizer, Cancer Institute of N.S.W, Speedel, Garnett Passe and Rodney Williams Memorial Foundation, Merck, Eli Lilly, P3 Panel (Commonwealth of Australia); Significant Financial Interest or Leadership Position: Schering-Plough, Pfizer, Daiichi-Sankyo and Cancer Institute of N.S.W. **Robert M. Carey, MD**—Financial or Business/Organizational Interests: Novartis, Pfizer, Daiichi-Sankyo; Significant Financial Interest or Leadership Position: none declared. **Carlos Fardella, MD**—Financial or Business/Organizational Interests: National Fund for Scientific and Technological Development (Fondo Nacional de Desarrollo Científico y Tecnológico [FONDECYT]); Significant Financial Interest or Leadership Position: none declared. **Celso E. Gomez-Sanchez, MD**—Financial or Business/Organizational Interests: American Heart Association; Significant Financial Interest or Leadership Position: Associate Editor for the journal *Hypertension*. **Franco Mantero, MD, PhD**—Financial or Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: Executive Committee of the International Society of Endocrinology. **Michael Stowasser, MBBS, FRACP, PhD**—Financial or Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: none declared. **William F. Young Jr., MSc, MD**—Financial or Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: Mayo Clinic, Clinical Endocrinology. **\*Victor M. Montori, MD**—Financial or Business/Organizational Interests: KER Unit (Mayo Clinic); Significant Financial Interest or Leadership Position: none declared.

*\*Evidence-based reviews for this guideline were prepared under contract with The Endocrine Society.*



8401 Connecticut Avenue, Suite 900  
 Chevy Chase, MD 20815-5817  
 Phone 301.941.0210; Fax 301.941.0257  
 societyservices@endo-society.org

FEIN 73-0521256

## THE ENDOCRINE SOCIETY GUIDELINE ORDER FORM

(Single reprint request for orders of 100 and less)

PRODUCTS	QTY.	PRICE (USD)		SUBTOTAL
		Member	Non-Member	
Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline		\$15.00	\$20.00	
Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline		\$15.00	\$20.00	
The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline		\$15.00	\$20.00	
Evaluation & Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline		\$15.00	\$20.00	
Evaluation & Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline		\$15.00	\$20.00	
Management of Thyroid Dysfunction during Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline		Executive Summary (MMTD07)—\$10.00	Executive Summary (MMTD07)—\$15.00	
		Guideline (MTSD07)— \$10.00	Guideline (MTSD07)— \$15.00	
Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline		\$15.00	\$20.00	
Miscellaneous				
<b>TOTAL</b>		All prices include sales tax		\$

**PAYMENT INFORMATION:**       Check       MasterCard       Visa

Card Number \_\_\_\_\_ Expiration Date \_\_\_\_\_

Billing Address \_\_\_\_\_ Signature \_\_\_\_\_

Are you a member of The Endocrine Society?       Yes       No

If you are a member and you know your member ID, please provide: \_\_\_\_\_

Prefix:	First Name (Given):	Middle:	Last (Surname):																			
Institution/Company:		Dept/Div:																				
Street/PO:																						
City:		State/Province:	Zip/Mail Code:      Country:																			
Telephone:		Fax:	Email:																			
Degree(s) that you would like listed after your name:		Professional Title:	Date of Birth:      Gender: <input type="radio"/> Male <input type="radio"/> Female																			
Which of the following best describes your primary professional role? (Please mark only one) <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"><input type="radio"/> Administrator</td> <td style="width: 50%; border: none;"><input type="radio"/> Retired</td> </tr> <tr> <td style="border: none;"><input type="radio"/> Basic Researcher</td> <td style="border: none;"><input type="radio"/> Teacher/Educator</td> </tr> <tr> <td style="border: none;"><input type="radio"/> Clinical Practitioner</td> <td style="border: none;"><input type="radio"/> Fellow (Clinical)</td> </tr> <tr> <td style="border: none;"><input type="radio"/> Clinical Researcher</td> <td style="border: none;"><input type="radio"/> Fellow (Postdoctoral/Research)</td> </tr> <tr> <td style="border: none;"><input type="radio"/> Industry/Corporate Professional</td> <td style="border: none;"><input type="radio"/> Student</td> </tr> <tr> <td style="border: none;"><input type="radio"/> Nurse/Healthcare Professional</td> <td style="border: none;"><input type="radio"/> Other _____</td> </tr> </table>			<input type="radio"/> Administrator	<input type="radio"/> Retired	<input type="radio"/> Basic Researcher	<input type="radio"/> Teacher/Educator	<input type="radio"/> Clinical Practitioner	<input type="radio"/> Fellow (Clinical)	<input type="radio"/> Clinical Researcher	<input type="radio"/> Fellow (Postdoctoral/Research)	<input type="radio"/> Industry/Corporate Professional	<input type="radio"/> Student	<input type="radio"/> Nurse/Healthcare Professional	<input type="radio"/> Other _____	Race or Ethnic Affiliation (voluntary) <table style="width: 100%; border: none;"> <tr><td style="border: none;"><input type="radio"/> African American, Black</td></tr> <tr><td style="border: none;"><input type="radio"/> Asian</td></tr> <tr><td style="border: none;"><input type="radio"/> Hispanic</td></tr> <tr><td style="border: none;"><input type="radio"/> Native American, Eskimo, Aleut</td></tr> <tr><td style="border: none;"><input type="radio"/> Pacific Islander</td></tr> <tr><td style="border: none;"><input type="radio"/> White, Caucasian</td></tr> <tr><td style="border: none;"><input type="radio"/> Other _____</td></tr> </table>	<input type="radio"/> African American, Black	<input type="radio"/> Asian	<input type="radio"/> Hispanic	<input type="radio"/> Native American, Eskimo, Aleut	<input type="radio"/> Pacific Islander	<input type="radio"/> White, Caucasian	<input type="radio"/> Other _____
<input type="radio"/> Administrator	<input type="radio"/> Retired																					
<input type="radio"/> Basic Researcher	<input type="radio"/> Teacher/Educator																					
<input type="radio"/> Clinical Practitioner	<input type="radio"/> Fellow (Clinical)																					
<input type="radio"/> Clinical Researcher	<input type="radio"/> Fellow (Postdoctoral/Research)																					
<input type="radio"/> Industry/Corporate Professional	<input type="radio"/> Student																					
<input type="radio"/> Nurse/Healthcare Professional	<input type="radio"/> Other _____																					
<input type="radio"/> African American, Black																						
<input type="radio"/> Asian																						
<input type="radio"/> Hispanic																						
<input type="radio"/> Native American, Eskimo, Aleut																						
<input type="radio"/> Pacific Islander																						
<input type="radio"/> White, Caucasian																						
<input type="radio"/> Other _____																						



# What goes into our Clinical Guidelines is a story worth telling

The extensive process that goes into creating The Endocrine Society's Clinical Guidelines not only provides validation and assurance, but also raises the standard for the development of guidelines everywhere.

The guidelines are developed using a multi-step process that reflects the standards of excellence embraced by The Endocrine Society.

## Endocrine Society Clinical Guidelines Now Available:

*Evaluation and Treatment of  
Adult Growth Hormone Deficiency*  
*Testosterone Therapy in Adult Men with  
Androgen Deficiency Syndromes*  
*Androgen Therapy in Women*  
*Management of Thyroid Dysfunction during  
Pregnancy and Postpartum*  
*Evaluation and Treatment of Hirsutism in  
Premenopausal Women*  
*The Diagnosis of Cushing's Syndrome*  
*Case Detection, Diagnosis, and Treatment of Patients  
with Primary Aldosteronism*

## Endocrine Society Clinical Guidelines Coming Soon:

- Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk
- Prevention and Treatment of Pediatric Obesity
- Evaluation and Management of Adult Hypoglycemic Disorders
- Endocrine Treatment of Adolescent & Adult Transsexuals
- Vitamin D & Bone
- Managing Patients Post-Bariatric Surgery
- Continuous Glucose Monitoring
- Congenital Adrenal Hyperplasia
- Lipids (with an endocrine focus)
- Pituitary Incidentaloma



To purchase the available guidelines visit:

[www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm](http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm).

To view patient guides (companion pieces to the clinical guidelines), visit

The Hormone Foundation's Web site at [www.hormone.org/public/patientguides.cfm](http://www.hormone.org/public/patientguides.cfm).



THE  
ENDOCRINE  
SOCIETY®

## Commercial Reprint Information

For information on reprint requests of more than 101 and commercial reprints contact:

Heather Edwards  
Reprint Sales Specialist  
Cadmus Professional Communications

Phone: 410.691.6214  
Fax: 410.684.2789  
Email: endoreprints@cadmus.com

## Single Reprint Information

For information on reprints of 100 and fewer, complete the guideline order form and return using one of the following methods:

Mail: The Endocrine Society  
c/o Bank of America  
P.O. Box 630721  
Baltimore, MD 21263-0736

Fax: 301.941.0257  
Email: Societyservices@endo-society.org

## Questions & Correspondences

The Endocrine Society  
Attn: Government & Public Affairs Department  
8401 Connecticut Avenue, Suite 900  
Chevy Chase, MD 20815

Phone: 301.941.0200  
Email: govt-prof@endo-society.org  
Web: www.endo-society.org

For more information on The Endocrine Society's Clinical Practice Guidelines or to download the complete version of this guideline, visit <http://www.endo-society.org/guidelines/index.cfm>.



The Endocrine Society  
8401 Connecticut Avenue, Suite 900  
Chevy Chase, MD 20815

301.941.0200  
[www.endo-society.org](http://www.endo-society.org)